Stocks Health care ONC
NASDAQ · Health careBeOne Medicines Ltd. (ONC)
BeOne Medicines Ltd. brought in $6.1B of revenue over the twelve months to June 30, 2026, up 34.3% from a year earlier. Net income was $655.7M, a net margin of 10.7%. Operating cash flow minus capital spending left $941.7M of free cash flow in fiscal 2025. At June 30, 2026 it held $5.1B in cash against $788.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
Watch ONC in 60 secondsWhat BeOne Medicines Ltd. does
BeOne Medicines, formerly known as BeiGene, is an oncology biotechnology company that discovers, develops, and commercializes targeted cancer therapies. It develops small-molecule drugs and monoclonal antibodies to treat various hematologic cancers and solid tumors for patients globally. Its shares trade on NASDAQ under the ticker ONC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $5.3B | $286.9M | $0.19 | $941.7M |
| 2024 | $3.8B | -$644.8M | -$0.47 | -$633.3M |
| 2023 | $2.5B | -$881.7M | -$0.65 | -$1.7B |
| 2022 | $1.4B | -$2B | -$1.49 | -$1.8B |
| 2021 | $1.2B | -$1.5B | -$1.21 | -$1.6B |
| 2020 | $308.9M | -$1.6B | -$1.50 | -$1.4B |
Full financial statements: income, balance sheet and cash flow
Where ONC ranks in Health care
Latest SEC filings
What BeOne Medicines Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 16, 2026Activist stake changed SCHEDULE 13D/A
- August 26, 2026
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 30% to $1.7B versus the same quarter last year; diluted EPS $0.16 versus $0.06.
- August 5, 2026
- June 26, 2026Other event 8-K
- June 15, 2026Activist stake changed SCHEDULE 13D/A
- June 11, 2026
- June 11, 2026
- May 15, 2026Other event 8-K
- May 14, 2026Passive stake changed SCHEDULE 13G/A
What is ONC worth? A DCF from its reported cash flow
Insider trades
What the people running BeOne Medicines Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $309.4M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 14, 2026 | Baker Bros. Advisors LPDirector | Exercised optionsindirect | 30,768 | $1.1M |
| September 14, 2026 | Baker Bros. Advisors LPDirector | Exercised optionsindirect | 30,768 | $1.1M |
| September 8, 2026 | Wang XiaodongDirector | Soldpre-planned (10b5-1) | 1,181 | $407.9K |
| September 8, 2026 | Wang XiaodongDirector | Soldpre-planned (10b5-1) | 2,841 | $983.4K |
| September 8, 2026 | Wang XiaodongDirector | Soldpre-planned (10b5-1) | 1,517 | $527K |
| September 8, 2026 | Wang XiaodongDirector | Soldpre-planned (10b5-1) | 1,721 | $598.9K |
| September 8, 2026 | Wang XiaodongDirector | Exercised options | 31,027 | $1.1M |
| September 8, 2026 | Wang XiaodongDirector | Soldpre-planned (10b5-1) | 7,492 | $2.6M |
| September 8, 2026 | Wang XiaodongDirector | Soldpre-planned (10b5-1) | 10,688 | $3.7M |
| September 8, 2026 | Wang XiaodongDirector | Soldpre-planned (10b5-1) | 6,569 | $2.3M |
| September 8, 2026 | Wang XiaodongDirector | Soldpre-planned (10b5-1) | 6,278 | $2.2M |
| September 1, 2026 | Ball Titus B.Principal Accounting Officer | Sold | 132 | $47K |
| August 25, 2026 | Wu XiaobinPresident and COO | Soldpre-planned (10b5-1) | 280 | $106.4K |
| August 12, 2026 | Oyler JohnChief Executive Officer, Director | Soldpre-planned (10b5-1) | 1,980 | $702.3K |
| August 12, 2026 | Oyler JohnChief Executive Officer, Director | Soldpre-planned (10b5-1) | 2,515 | $896.4K |
Who owns ONC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Julian C. Baker13D, may seek influence with 4 related filers | 7.8% | September 16, 2026 |
Largest institutional holders
Insiders
15 insiders reported holding 22,855,641 shares in total, about $8.39B at the last price.
| Holder | Shares |
|---|---|
| Baker Bros. Advisors LPDirector | 8,260,7298,260,729 held indirectly |
| Oyler JohnChief Executive Officer, Director | 5,697,649 |
| Wang XiaodongDirector | 4,682,493 |
| Wang LaiPresident, Global Head of R&D | 1,710,085 |
| Wu XiaobinPresident and COO | 1,308,161 |
| Rosenberg AaronChief Financial Officer | 397,891 |
| Lee Chan HenrySVP, General Counsel | 346,554 |
| Ball Titus B.Principal Accounting Officer | 99,645 |
| Hooper Anthony CDirector | 83,720 |
| Riva AlessandroDirector | 73,164 |
Questions about ONC
What does BeOne Medicines Ltd. do?
BeOne Medicines, formerly known as BeiGene, is an oncology biotechnology company that discovers, develops, and commercializes targeted cancer therapies. It develops small-molecule drugs and monoclonal antibodies to treat various hematologic cancers and solid tumors for patients globally. Its shares trade on NASDAQ under the ticker ONC.
Is BeOne Medicines Ltd. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $655.7M on revenue of $6.1B, a net margin of 10.7%.
How much revenue does BeOne Medicines Ltd. make?
Over the twelve months to June 30, 2026 BeOne Medicines Ltd. reported revenue of $6.1B. That is 34.3% more than a year earlier.
When did BeOne Medicines Ltd. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the activist stake changed from September 16, 2026.
Similar companies
Compare ONC with
Follow ONC
Get an email when BeOne Medicines Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ONC: get an email when it filesWhere the numbers come from
Financial figures are the values BeOne Medicines Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.